WO2021224942A1 - Formes polymorphes de benzoate d'amlodipine et leur procédé de préparation - Google Patents

Formes polymorphes de benzoate d'amlodipine et leur procédé de préparation Download PDF

Info

Publication number
WO2021224942A1
WO2021224942A1 PCT/IN2021/050433 IN2021050433W WO2021224942A1 WO 2021224942 A1 WO2021224942 A1 WO 2021224942A1 IN 2021050433 W IN2021050433 W IN 2021050433W WO 2021224942 A1 WO2021224942 A1 WO 2021224942A1
Authority
WO
WIPO (PCT)
Prior art keywords
amlodipine
amlodipine benzoate
crystalline
benzoate
xrpd
Prior art date
Application number
PCT/IN2021/050433
Other languages
English (en)
Inventor
Daniel Levin
Jayprakash PARIHAR
Prashant Pawar
Pramod CHAUDHARI
Jamankumar MANDAVIYA
Dattatray SHEJUL
Sitasharan RAY
Original Assignee
Alkem Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd. filed Critical Alkem Laboratories Ltd.
Publication of WO2021224942A1 publication Critical patent/WO2021224942A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the present invention relates to the polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof.
  • the present invention also relates to the processes for the preparation of Amlodipine benzoate.
  • the present invention further relates to the manufacturing processes for the preparation of crystalline Amlodipine benzoate.
  • Amlodipine benzoate chemically known as 3-Ethyl-5-methyl ( ⁇ )-2-[(2- aminoethoxy)methyl]-4-(2-chlorophenyl)-l,4-dihydro-6-methyl-3,5- pyridinedicarboxylate benzenecarboxylate is benzoate salt of Amlodipine and is represented by the formula I.
  • Amlodipine benzoate is the active ingredient of the drug Katerzia® and intended for oral suspension. Amlodipine benzoate is a calcium channel blocker and is intended for the treatment of hypertension by reducing the blood pressure and thus reducing the risk of various cardiovascular events.
  • Prior to Katrezia® W02005/089353 generically disclosed (S)- Amlodipine benzoate as the first intermediate salt during the preparation of (S)-Amlodipine maleate.
  • the PCT doesn’t disclose specific preparation or isolation of (S)-Amlodipine benzoate.
  • CN110372575 discloses eutectic crystal of dihydropyridine calcium antagonist.
  • the disclosed eutectic crystal has molecular formula: (C 20 H 25 CIN 2 O 5 ) (CeHsCOOH) (Y) n , wherein Y is any one of water molecule, ethanol molecule or isopropanol molecule, 0 ⁇ n ⁇ 3, C 20 H 25 CIN 2 O 5 is levamlodipine, C 6 H 5 COOH is benzoic acid.
  • WO20 18/067959 relates to the oral liquid formulation of Amlodipine benzoate, wherein the process for the preparation of oral liquid formulation comprises formation of Amlodipine benzoate in situ by reaction of more aqueous soluble Amlodipine salt (Amlodipine besylate or other Amlodipine salts) than Amlodipine benzoate, with a molar excess of sodium benzoate in the presence of at least one additional excipient.
  • a particular polymorphic form of a compound may have certain physical properties that differ from those of any other crystalline or amorphous forms and such properties may influence markedly the chemical and pharmaceutical processing of compound, particularly when the compound is prepared or used on a commercial scale.
  • each crystal form of a compound may show differences in physical properties such as crystalline size and shape, melting point, density, hygroscopicity, solubility, suspending properties and stability.
  • the more stable crystalline form is more suitable for formulation and processing on a commercial scale.
  • Amlodipine and its various pharmaceutically acceptable salts have been studied since decades. US4572909 disclosed Amlodipine and pharmaceutically acceptable salts such as, hydrochloride, hydrobromide, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate and gluconate salts.
  • US4879303 & US6846931 disclosed Amlodipine besylate and Amlodipine pyroglutamate, respectively. Further, there are several prior-arts disclosing preparation of these salts, wherein the process comprises conversion of protected Amlodipine to Amlodipine free base followed by its conversion to desired salt. Particularly, US20020143046, W02005023769, CN102659673, CN105732482, CN103006648 and CN107445889 discloses conversion of Phthaloyl Amlodipine to Amlodipine free base followed by its conversion to desired salt, preferably in situ (without free base isolation).
  • Phthaloyl amlodipine is preferably treated with aqueous solutions of primary amines in water immiscible solvents followed by treatment of the organic phase with suitable organic acids to give amlodipine in the form of a pharmaceutically acceptable salt.
  • Scheme-1 Generic representation of conversion of Phthaloyl Amlodipine to Amlodipine Salt can be depicted as Scheme-1:
  • W02019/200143 discloses a process for conversion of Amlodipine salt (preferably besylate) having more aqueous solubility to Amlodipine benzoate in the presence of sodium benzoate by ultrasonic agitation.
  • the process disclosed therein has one or more issues while scaling up, particularly ultrasonic agitation step.
  • the process comprise conversion of the first Amlodipine salt to final Amlodipine benzoate.
  • the overall Amlodipine benzoate manufacturing process comprises an additional step of isolating the first Amlodipine salt.
  • the inventors of the present invention have developed novel Amlodipine benzoate crystalline forms, possessing desirable processing properties.
  • the inventors of the present invention have addressed the need of developing an industrial viable process for the preparation of Amlodipine benzoate which can overcome the drawbacks associated with the known processes and result in the desired polymorph of Amlodipine benzoate with substantial purity and yield.
  • the primary objective of the present invention is to provide novel polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. Another objective of the present invention is to provide an industrial viable process for the synthesis of Amlodipine benzoate.
  • Another objective of the present invention is to provide a process for the preparation of novel polymorphic forms of Amlodipine benzoate.
  • the present invention provides a crystalline hydrate of Amlodipine benzoate.
  • the present invention provides a crystalline dihydrate Form-I of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.9, 10.7 and 13.7 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate.
  • the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a.
  • the present invention provides crystalline anhydrous form of Amlodipine benzoate.
  • the present invention provides a crystalline Form-II of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline Form-II of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. removing water from the organic layer; c. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and d. isolating crystalline Form-II of Amlodipine benzoate.
  • the present invention provides a crystalline Form-Ill of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline Form-Ill of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent, selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent, selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof; and c. isolating crystalline Form-Ill of Amlodipine benzoate.
  • the present invention provides a crystalline monohydrate Form-IV of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 6.71 and 7.93 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline monohydrate Form-IV of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a Ethyl acetate; and c. isolating crystalline monohydrate Form-IV of Amlodipine benzoate.
  • the present invention provides a process for preparing Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent; and c. isolating Amlodipine benzoate.
  • the present invention provides an amorphous Amlodipine benzoate.
  • the present invention provides a pharmaceutical composition containing a hydrate, crystalline form or amorphous form of Amlodipine benzoate.
  • ambient temperature refers to a temperature ranging from about 15°C to 35°C, preferably the ambient temperature refers to a temperature from about 20°C to 30°C, more preferably to a temperature of 25°C.
  • hydrate refers to the crystalline solid adducts containing either stoichiometric or nonstoichiometric amounts of water incorporated within the crystal structure. Hydrates can be defined based on the moles of water incorporated within the crystal structure one mole of Amlodipine benzoate. “Monohydrate” stands for one mole of water with respect to one mole of Amlodipine benzoate; “dihydrate” stands for two moles of water with respect to one mole of Amlodipine benzoate; and similarly “hemihydrate” and “sesquihydrate” stands for half and 1.5 moles of water with respect to one mole of Amlodipine benzoate. The same can be indicated as percentage (%) weight of water with respect to weight of Amlodipine benzoate. The percentage (%) weight of water can be obtained by various analytical tools; preferably, Karl-Fischer titration and Thermal Gravimetric Analysis.
  • anhydrous refers to the crystalline or amorphous solid adducts containing undetectable bound water, incorporated within the crystal structure.
  • the term “remove water” or “removing water” stands for removing or separating trace amount of water from a mixture of organic solution with water by the means of distillation, physical adsorption or chemical methods.
  • azeotropically or “azeotropic distillation” stands for the process to break azeotrope and to separate two close-boiling components, facilitated by dean-stark apparatus.
  • contacting includes mixing, adding, slurrying, stirring or a combination thereof.
  • the term “about” are to be construed as modifying a term or value such that it is not an absolute. Such terms will be defined by the circumstances. This includes, at the very least, the degree of expected experimental error, technique error and instrument error for a given technique used to measure a value.
  • XRPD X-ray powder diffraction
  • TGA thermogram endothermic / exothermic peak positions TGA thermogram endothermic / exothermic peak positions
  • typical peak position and intensity variability are taken into account.
  • the peak position (2 theta) will show some inter-apparatus variability, typically as much as 0.2°.
  • relative peak intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, prepared sample surface and other factors known to those skilled in the art and should be taken as quantitative measure only.
  • Fig. 1 represents an X-ray powder diffraction (XRPD) pattern of the crystalline hydrate Form-I of Amlodipine benzoate prepared as per Example 1;
  • Fig. 2 represents a thermal gravimetric analysis (TGA) of the crystalline hydrate Form-I of Amlodipine benzoate of the present invention;
  • Fig. 3 represents differential scanning calorimetry (DSC) of the crystalline hydrate Form-I of Amlodipine benzoate of the present invention
  • Fig. 4 represents an X-ray powder diffraction (XRPD) pattern of the crystalline Form-II of Amlodipine benzoate prepared as per Example 2;
  • Fig. 5 represents a thermal gravimetric analysis (TGA) of the crystalline Form -II of Amlodipine benzoate of the present invention;
  • Fig. 6 represents differential scanning calorimetry (DSC) of the crystalline Form-II of Amlodipine benzoate of the present invention
  • Fig. 7 represents an X-ray powder diffraction (XRPD) pattern of the crystalline Form-Ill of Amlodipine benzoate prepared as per Example 3;
  • Fig. 8 represents a thermal gravimetric analysis (TGA) of the crystalline Form-Ill of Amlodipine benzoate of the present invention
  • Fig. 9 represents differential scanning calorimetry (DSC) of the crystalline Form- Ill of Amlodipine benzoate of the present invention.
  • Fig. 10 represents an X-ray powder diffraction (XRPD) pattern of the crystalline monohydrate Form-IV of Amlodipine benzoate prepared as per Example 4;
  • Fig. 11 represents an X-ray powder diffraction (XRPD) pattern of the amorphous Amlodipine benzoate prepared as per Example 5;
  • the present invention provides crystalline hydrate of Amlodipine benzoate.
  • the crystalline hydrate of present invention contains from about 1.5% to about 12.7% w/w of water by Karl-Fischer titration.
  • the present invention provides a crystalline hydrate Form-I of Amlodipine benzoate.
  • the crystalline hydrate Form-I of Amlodipine benzoate contains about 6.3% w/w of water by Karl-Fischer titration.
  • the crystalline hydrate Form-I of Amlodipine benzoate according to the present invention is a di-hydrate of Amlodipine benzoate.
  • the crystalline dihydrate Form-I of Amlodipine benzoate is characterized by at least one of the following: a.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • the crystalline dihydrate Form-I of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 9.7, 15.7, 19.2, 22.0, 24.9 and 25.6 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine; optionally in methyl tert-butyl ether to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate.
  • Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
  • Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline hydrate Form-I of Amlodipine benzoate.
  • the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline hydrate Form-I of Amlodipine benzoate.
  • Step (c), wherein the crystalline hydrate Form-I of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combinations thereof.
  • the crystalline hydrate Form-I may optionally be washed with methyl tert-butyl ether.
  • crystalline hydrate Form-I is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water.
  • the crystalline hydrate Form-I of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline anhydrous form of Amlodipine benzoate.
  • the crystalline anhydrous form of Amlodipine benzoate contains less than 1% w/w of water by Karl-Fischer titration.
  • the present invention provides a crystalline Form -II of Amlodipine benzoate.
  • the crystalline Form-II of Amlodipine benzoate contains about 0.21% w/w of water by Karl-Fischer titration.
  • the crystalline Form-II of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1 ⁇ 0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 4; b. by a weight loss of about less than 1% as measured by thermal gravimetric analysis (TGA) and a thermal gravimetric thermogram substantially the same as depicted in Fig. 5; or c. by DSC endotherm with onset temperature at 136.86°C and a DSC pattern substantially the same as depicted in Fig. 6.
  • XRPD X-ray powder diffraction
  • TGA thermal gravimetric analysis
  • a thermal gravimetric thermogram substantially the same as depicted in Fig. 5
  • the crystalline Form-II of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 8.5, 11.9, 19.9, 20.5, 20.9, 22.3, 23.0 and 23.8 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline Form-II of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. removing water from the organic layer; c. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and d. isolating crystalline Form-II of Amlodipine benzoate.
  • Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20 to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (b), wherein calculated amount of water may be removed by either of the methods known to the skilled practitioner, such as distillation, physical adsorption (molecular sieve, anhydrous sodium sulfate, anhydrous magnesium sulfate), chemical water removal or combination thereof.
  • the water is removed by distillation. More preferably, by carrying out azeotropic distillation using dean- stark apparatus.
  • Step (b) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (b) and the reaction mixture is directly contacted with benzoic acid.
  • Step (c) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline Form-II of Amlodipine benzoate.
  • the step c) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline Form-II of Amlodipine benzoate.
  • Step (d), wherein the crystalline Form-II of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof.
  • the crystalline Form-II may optionally be washed with methyl tert-butyl ether.
  • crystalline Form-II is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water.
  • the crystalline Form-II of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline Form-Ill of Amlodipine benzoate.
  • the crystalline Form-Ill of Amlodipine benzoate contains about 0.15% w/w of water.
  • the crystalline Form-Ill of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6 ⁇ 0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 7; or b. by DSC endotherm with onset temperature at 125.96°C and a DSC pattern substantially the same as depicted in Fig. 9.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • the crystalline Form-Ill of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline Form-Ill of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof; and c. isolating crystalline Form-Ill of Amlodipine benzoate.
  • Steps (a) and (b), wherein the solvent may be selected from the group comprising toluene, xylene, dichloromethane or mixture thereof.
  • the solvent may be selected from toluene or dichloromethane. More preferably, the solvent is toluene.
  • Step (a) may be carried out at ambient temperatures to 120°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
  • Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline Form-Ill of Amlodipine benzoate.
  • the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline Form-Ill of Amlodipine benzoate.
  • Step (c), wherein the crystalline Form-Ill of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof.
  • the crystalline Form-Ill may optionally be washed with the solvent selected from toluene, xylene, dichloromethane or mixture thereof.
  • the crystalline Form-Ill is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water.
  • the crystalline Form-Ill of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline monohydrate Form-IV of Amlodipine benzoate.
  • the crystalline Form-IV of Amlodipine benzoate contains about 0.15% w/w of water.
  • the crystalline monohydrate Form-IV of Amlodipine benzoate is characterized by X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6 ⁇ 0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 10;
  • the crystalline monohydrate Form-IV of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 4.1, 5.6, 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline Form-IV of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a ethyl acetate; and c. isolating crystalline monohydrate Form-IV of Amlodipine benzoate.
  • the present invention provides a process for preparing Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine optionally in a solvent to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent; and c. isolating Amlodipine benzoate.
  • the solvent may be selected from ethanol, methyl tert-butyl ether, toluene or mixture thereof. More preferably, the solvent may be selected from methyl tert-butyl ether, ethyl acetate or toluene.
  • Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the organic solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (a) may further comprise removal of calculated amount of water from the organic layer by either of the methods known to the skilled practitioner, such as distillation, physical adsorption (molecular sieve, anhydrous sodium sulfate, anhydrous magnesium sulfate), chemical water removal or combination thereof.
  • the water may be removed by distillation. More preferably, by carrying out azeotropic distillation using dean-stark apparatus.
  • Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
  • Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain Amlodipine benzoate.
  • the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain Amlodipine benzoate.
  • Step (c), wherein Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof.
  • the isolated Amlodipine benzoate may optionally be washed with a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether, methyl tert-butyl ether, ethyl acetate, 1,4-dioxane, dichloromethane, heptane, xylene, toluene or mixture thereof.
  • a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether, methyl tert-butyl ether, ethyl acetate, 1,4-dioxane, dichloromethane, heptane, xylene, toluene or mixture thereof.
  • a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether,
  • Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline form of Amlodipine benzoate having a purity by HPLC of >99%.
  • a purity by HPLC of >99.5% more particularly, a purity by HPLC of >99.8%, most particularly, a purity by HPLC of >99.9%.
  • compositions comprising Amlodipine Benzoate in an amorphous form or crystalline Form 1, Form -II, Form -III, Form- IV or a acceptable hydrate or solvate thereof, as an active pharmaceutical ingredient, in combination with one or more pharmaceutically acceptable carriers or excipients.
  • excipients to a large extent, depends on factors, such as the particular mode of administration, the effect of the excipient on the solubility and stability of the active ingredient, and the nature of the dosage form.
  • the pharmaceutical composition described herein is preferably an Amlodipine Oral Liquid Formulation.
  • the oral liquids pharmaceutical composition may include, but are not limited to, solutions (both aqueous and nonaqueous), suspensions, emulsions, syrups, slurries, juices, elixirs, dispersions, and the like. It is envisioned that solution/suspensions are also included where certain components described herein are in a solution while other components are in a suspension. In some embodiments, the oral liquid formulation is a suspension.
  • XRPD X-ray diffraction data is obtained using a Bruker AXS D8 advance (or) equivalent X-ray Diffractometer, CuKa radiation, wavelength 1.54 A.
  • TGA TGA measurement is performed using a TGA55; TRIOS software V4.3.1.39215, temperature range 30°C-300°C and 10°C/min.
  • DSC DSC measurement is performed using DSC25; TRIOS software V4.3.1.39215, temperature range 25°C-300°C and 5°C/min.
  • KF KF results is obtained using Metrohm; 870KF Titrino plus.
  • Example-1 Process of Crystalline hydrate Form-I of Amlodipine benzoate
  • Phthaloyl amlodipine (25.0 g, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 75 ml, 3.0 volumes) at 30°C-50°C in methyl tert-butyl ether (250 ml, 10.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (50 ml X 2 times). Washed the combined methyl tert-butyl ether layer with water (50 ml X 2 times).
  • Example-la Process of crystalline dihydrate Form I of Amlodipine benzoate
  • Phthaloyl amlodipine (301.5 gm, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 1200 ml, 4.0 volumes) at 30°C-37°C and maintained for 12 hours.
  • aqueous monomethyl amine solution (Aqueous 40%, 150 ml, 0.5 volumes) at 30°C-37°C, stirred for 12 and then stirred for 8 hours at 40°C-46 0 C.
  • water 600 ml, 2 volume
  • the isolated solid was washed with water (1200 ml, 4 volume).
  • the isolated wet solid was partitioned between ethyl acetate (2400 ml, 8 volume) and water (300 ml,
  • Example-2 Process of Crystalline Form-II of Amlodipine benzoate Phthaloyl amlodipine (50g, 1.0 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 200 ml, 4.0 volume) at 30°C -50°C in methyl tert- butyl ether (500ml, 10.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (100 ml X 2 times). Washed the combined methyl tert-butyl ether layer was washed water (100 ml X 2 times).
  • Example-3 Process of crystalline Form-Ill of Amlodipine benzoate
  • Phthaloyl amlodipine (20g, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 80 ml, 4.0 volume) at 30°C -50 °C in toluene (100 ml, 5.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with toluene (20 ml X 2 times). Washed the combined toluene layer with water (40 ml X 3 times). Distilled out approximately 1.0 volume of toluene (20 ml) under vacuum below 40°C. Cooled the reaction mass to 10°C -30°C and added toluene (180ml, 9.0 volume) to the reaction mass.
  • Example-4 Process of crystalline monohydrate Form IV of Amlodipine benzoate
  • Phthaloyl amlodipine (151.0 gm, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 600 ml, 4.0 volumes) at 25°C -35 0 C and maintained for 23 hours. After completion of reaction, added water (300 ml, 2 volume) into the reaction mass and filtered the solid after maintaining the reaction mass at 0°C -10°C for 2 hours. The isolated solid was washed with water (600 ml, 4 volume).
  • the isolated wet solid (20gm equivalent) was dissolved in ethyl acetate (200 ml, 10 volume) and cooled to 0°C -10 °C followed by addition of benzoic acid (4.1 gm, 0.90 equivalent) dissolved in the ethyl acetate (40 ml, 2 volume).
  • the wet solid was isolated after filtration followed by ethyl acetate washing (40 ml, 2 volume).
  • the Amlodipine benzoate monohydrate was obtained after drying the wet solid at 30°C - 42 °C for 8 hours.
  • Phthaloyl amlodipine (lOOg, 1.0 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 400 ml, 4.0 volume) at 30°C -50 °C in methyl tert- butyl ether (1000ml, 10.0 volume) for 8-10 hours. After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (200 ml X 2 times). Washed the combined methyl tert-butyl ether layer was washed water (200 ml X 4 times). Added methyl tert-butyl ether (200 ml, 2.0 volume) in to the organic layer and filtered through Cellite bed.
  • aqueous monomethyl amine solution Aqueous 40%, 400 ml, 4.0 volume
  • methyl tert-butyl ether 1000ml, 10.0 volume
  • organic layer was separated and aqueous layer back extracted with methyl tert-butyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes polymorphes de benzoate d'amlodipine et des compositions pharmaceutiques associées. En particulier, la présente invention concerne des formes hydratées cristallines et des formes anhydres cristallines de benzoate d'amlodipine. La présente invention concerne également un procédé de préparation des formes polymorphes selon l'invention. La présente invention concerne en outre un procédé de préparation de benzoate d'amlodipine.
PCT/IN2021/050433 2020-05-06 2021-05-04 Formes polymorphes de benzoate d'amlodipine et leur procédé de préparation WO2021224942A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021019251 2020-05-06
IN202021019251 2020-05-06

Publications (1)

Publication Number Publication Date
WO2021224942A1 true WO2021224942A1 (fr) 2021-11-11

Family

ID=78467951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050433 WO2021224942A1 (fr) 2020-05-06 2021-05-04 Formes polymorphes de benzoate d'amlodipine et leur procédé de préparation

Country Status (1)

Country Link
WO (1) WO2021224942A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107445889A (zh) * 2017-08-01 2017-12-08 东瑞（南通）医药科技有限公司 一种一锅法制备苯磺酸氨氯地平
US20180098978A1 (en) * 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180098978A1 (en) * 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN107445889A (zh) * 2017-08-01 2017-12-08 东瑞（南通）医药科技有限公司 一种一锅法制备苯磺酸氨氯地平

Similar Documents

Publication Publication Date Title
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
JP6554617B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形
EP2502917A1 (fr) Formes cristallines à l'état solide de 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
EP2350055A1 (fr) Solvates de lénalidomide et procédés correspondants
WO2007109799A2 (fr) Polymorphes de malate d'eszopiclone
WO2008084494A1 (fr) Nouvelles formes polymorphes de dihydrogénophosphate de carvedilol et procédé de préparation de celles-ci
US20060167265A1 (en) Process for making amlodipine, derivatives thereof, and precursors therefor
JP2002528436A (ja) アムロジピン合成用中間体、その調製方法および使用方法
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
EP2975032A1 (fr) Formes cristallines d'un médicament antidépresseur
JP2011516519A (ja) アルガトロバン一水和物の多形体及びその合成方法
CN114437084A (zh) 杂环类化合物及其制备方法和应用
US9815844B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US8344159B2 (en) Carvedilol phosphate sesquihydrate
WO2021224942A1 (fr) Formes polymorphes de benzoate d'amlodipine et leur procédé de préparation
US9458146B2 (en) Crystalline sodium salt of an HIV integrase inhibitor
WO2005023769A1 (fr) Procede pour l'elaboration de sels d'amlodipine
EP2072510A1 (fr) Forme cristalline d'azélastine
EP3976598B1 (fr) Sels d'addition d'acide antagonistes de l'histamine h3 sélectifs et leur procédé de préparation
US20220227769A1 (en) Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
EP4232435A1 (fr) Procédés de préparation de polymorphes d'ivabradine hci
EP3210975A1 (fr) Co-cristaux de lorcaserine
WO2022264072A1 (fr) Polymorphes d'acide 2-(3,5-dichlorophényl)-l,3-benzoxazole-6-carboxylique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21799527

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21799527

Country of ref document: EP

Kind code of ref document: A1